These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6187015)

  • 1. Artificial Salmonella vaccines.
    Svenson SB; Lindberg AA
    Prog Allergy; 1983; 33():120-43. PubMed ID: 6187015
    [No Abstract]   [Full Text] [Related]  

  • 2. Protection against oral challenge three months after i.v. immunization of BALB/c mice with live Aro Salmonella typhimurium and Salmonella enteritidis vaccines is serotype (species)-dependent and only partially determined by the main LPS O antigen.
    Hormaeche CE; Mastroeni P; Harrison JA; Demarco de Hormaeche R; Svenson S; Stocker BA
    Vaccine; 1996 Mar; 14(4):251-9. PubMed ID: 8744548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines.
    Tacket CO; Ferreccio C; Robbins JB; Tsai CM; Schulz D; Cadoz M; Goudeau A; Levine MM
    J Infect Dis; 1986 Aug; 154(2):342-5. PubMed ID: 2425009
    [No Abstract]   [Full Text] [Related]  

  • 4. Why are the killed S. typhi vaccines ineffective.
    Barber C
    Zentralbl Bakteriol A; 1980 Mar; 246(2):184-90. PubMed ID: 6775438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo evidence of immunological masking of the Vibrio cholerae O antigen of a hybrid Salmonella typhi Ty21a-Vibrio cholerae oral vaccine in humans.
    Forrest BD; LaBrooy JT
    Vaccine; 1991 Jul; 9(7):515-20. PubMed ID: 1716810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demonstration of specific IgA in human feces after immunization with live Ty21a Salmonella typhi vaccine.
    Cancellieri V; Fara GM
    J Infect Dis; 1985 Mar; 151(3):482-4. PubMed ID: 3882850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological response of patients infected with Salmonella typhi.
    Chart H; Rowe B; Cheesbrough JS
    J Clin Pathol; 1997 Nov; 50(11):944-6. PubMed ID: 9462246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the response to the enterobacterial common antigen after typhoid vaccination.
    Milhomem AM; Suassuna I
    Rev Soc Bras Med Trop; 1987; 20(1):7-12. PubMed ID: 3507980
    [No Abstract]   [Full Text] [Related]  

  • 9. Experience with Salmonella typhi Vi capsular polysaccharide vaccine.
    Hessel L; Debois H; Fletcher M; Dumas R
    Eur J Clin Microbiol Infect Dis; 1999 Sep; 18(9):609-20. PubMed ID: 10534182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant live Salmonella spp. for human vaccination against heterologous pathogens.
    Bumann D; Hueck C; Aebischer T; Meyer TF
    FEMS Immunol Med Microbiol; 2000 Apr; 27(4):357-64. PubMed ID: 10727892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Basic studies on prevention of experimental salmonellosis (1). Distribution of SPA producing strains of S. enteritidis and correlation of protective immunity between SPA and killed vaccine (author's transl)].
    Sugihara H; Tanaka T; Kamiya K
    Kansenshogaku Zasshi; 1980 Jan; 54(1):3-10. PubMed ID: 6768821
    [No Abstract]   [Full Text] [Related]  

  • 12. Live oral typhoid vaccine Salmonella Typhi Ty21a - a surrogate vaccine against non-typhoid salmonella?
    Kantele A; Pakkanen SH; Siitonen A; Karttunen R; Kantele JM
    Vaccine; 2012 Nov; 30(50):7238-45. PubMed ID: 23084770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Salmonella porins as a broad spectrum vaccine candidate.
    Tabaraie B; Sharma BK; Sharma PR; Sehgal R; Ganguly NK
    Microbiol Immunol; 1994; 38(7):553-9. PubMed ID: 7968689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of antibodies against Salmonella typhi OmpC porin by naked DNA immunization.
    López-Macías C; López-Hernández MA; González CR; Isibasi A; Ortiz-Navarrete V
    Ann N Y Acad Sci; 1995 Nov; 772():285-8. PubMed ID: 8546410
    [No Abstract]   [Full Text] [Related]  

  • 15. [Factors of Salmonella typhi virulence in relation to the development of new vaccines].
    García JA; Paniagua J; Pelayo R; Isibasi A; Kumate J
    Salud Publica Mex; 1992; 34(3):262-7. PubMed ID: 1615345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and antigenicity of typhoid-Shigella sonnei vaccine (strain 5076-1C).
    Tramont EC; Chung R; Berman S; Keren D; Kapfer C; Formal SB
    J Infect Dis; 1984 Feb; 149(2):133-6. PubMed ID: 6366077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoblot analysis of Salmonella typhi lipopolysaccharide (LPS) using typhoid sera.
    Vullo V; Mastroianni CM; Contini C; Cignarella L; Massetti AP; Falciano M; Paoletti F; Di Seri M
    Boll Ist Sieroter Milan; 1987; 66(2):130-3. PubMed ID: 2444235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salmonella typhi O-polysaccharide--tetanus toxoid conjugated vaccine.
    Saxena M; Di Fabio JL
    Vaccine; 1994 Aug; 12(10):879-84. PubMed ID: 7526567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agglutinogens, White's 'Q' substance and the common proteins of Enterobacteriaceae.
    Barber C
    Microbios; 1984; 41(160):79-86. PubMed ID: 6377018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenic complexes obtained from Salmonella typhi-murium and Salmonella typhi Ty2 by the bacterial acetone powder method.
    Tato P; Flisser A; Gavilanes M; Molinari JL
    Ann Microbiol (Paris); 1979 Jan; 130 A(1):47-60. PubMed ID: 382951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.